Results 11 to 20 of about 104,116 (405)

Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl

JAMA Network Open, 2023
This cohort study examines the incidence of precipitated withdrawal comparing traditional sublingual buprenorphine with a 7-day extended-release injectable initiated in the emergency department (ED).
G. D'Onofrio, Kathryn F. Hawk, J. Perrone, S. Walsh, Michelle R. Lofwall, D. Fiellin, A. Herring   +6 more
semanticscholar   +1 more source

ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids.

Journal of addiction medicine, 2023
Treatment of opioid use disorder (OUD) with buprenorphine has evolved considerably in the last decade as the scale of the OUD epidemic has increased along with the emergence of high-potency synthetic opioids (HPSOs) and stimulants in the drug supply ...
M. Weimer, A. Herring, S. S. Kawasaki, M. Meyer, Bethea A. Kleykamp, Kelly S Ramsey   +5 more
semanticscholar   +1 more source

Evidence on Buprenorphine Dose Limits: A Review

Journal of addiction medicine, 2023
Objectives As overdose deaths from fentanyl continue to increase, optimizing use of medications for opioid use disorder has become increasingly important. Buprenorphine is a highly effective medication for reducing the risk of overdose death, but only if
L. Grande, D. Cundiff, M. Greenwald, M. Murray, T. Wright, Stephen A. Martin   +5 more
semanticscholar   +1 more source

Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder

JAMA Network Open, 2023
Key Points Question Does implementation facilitation (IF) increase adoption of emergency department (ED)–initiated buprenorphine and patient engagement in opioid use disorder treatment compared with grand rounds?
G. D'Onofrio, E. J. Edelman, Kathryn F. Hawk, M. Chawarski, M. Pantalon, P. Owens, Shara Martel, R. Rothman, M. Saheed, R. Schwartz, E. Cowan, L. Richardson, E. Salsitz, M. Lyons, C. Freiermuth, C. Wilder, L. Whiteside, J. Tsui, Jared W Klein, E. Coupet, P. O'Connor, Abigail G Matthews, Sean M. Murphy, Kristen Huntley, D. Fiellin   +24 more
semanticscholar   +1 more source

Buprenorphine [PDF]

Acta Crystallographica Section E Structure Reports Online, 2014
In the crystal structure of a semi-synthetic opioid drug buprenorphine, C29H41NO4{systematic name: (2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-3-hydroxy-6-methoxy-4,5-epoxy-6,14-ethanomorphinan-7-yl]-3,3-dimethylbutan-2-ol}, the cyclopropylmethyl group is disordered over two sites with an occupancy factor of 0.611 (3) for the major component.
Jaroslaw Mazurek, Marcel Hoffmann, Anna Fernandez Casares, Phillip D. Cox, Mathew D. Minardi   +4 more
openaire   +3 more sources

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees

JAMA Network Open, 2023
Key Points Question Was telemedicine initiation for buprenorphine treatment associated with changes in treatment retention or opioid-related nonfatal overdose?
Lindsey R. Hammerslag, Aimee Mack, Redonna K. Chandler, Laura C. Fanucchi, Daniel J. Feaster, Marc R. Larochelle, Michelle R. Lofwall, Michael Nau, Jennifer Villani, Sharon L. Walsh, P. Westgate, S. Slavova, Jeffery Talbert   +12 more
semanticscholar   +1 more source

Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study

Harm Reduction Journal, 2023
Background Recent policies have lessened restrictions around prescribing buprenorphine-naloxone (buprenorphine) for the treatment of opioid use disorder (OUD).
Joëlla W. Adams, Michael Duprey, Sazid Khan, Jessica Cance, Donald P. Rice, Georgiy Bobashev   +5 more
doaj   +1 more source

Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic

JAMA Network Open, 2023
Key Points Question Did buprenorphine-involved overdose deaths change after implementing prescribing flexibilities during the COVID-19 pandemic? Findings In this cross-sectional study including 74 474 opioid-involved overdose deaths, buprenorphine was ...
Lauren J Tanz, Christopher M. Jones, N. Davis, W. Compton, G. Baldwin, B. Han, N. Volkow   +6 more
semanticscholar   +1 more source

Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation

Harm Reduction Journal, 2022
Background Syringe services programs (SSPs) hold promise for providing buprenorphine treatment access to people with opioid use disorder (OUD) who are reluctant to seek care elsewhere.
Andrea Jakubowski, Caroline Rath, Alex Harocopos, Monique Wright, Alice Welch, Jessica Kattan, Czarina Navos Behrends, Teresa Lopez-Castro, Aaron D. Fox   +8 more
doaj   +1 more source

Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.

New England Journal of Medicine, 2022
BACKGROUND Opioid agonist therapy is strongly recommended for pregnant persons with opioid use disorder. Buprenorphine may be associated with more favorable neonatal and maternal outcomes than methadone, but existing data are limited.
Elizabeth A. Suarez, K. Huybrechts, L. Straub, S. Hernández-Díaz, H. Jones, H. Connery, J. Davis, K. Gray, B. Lester, M. Terplan, H. Mogun, B. Bateman   +11 more
semanticscholar   +1 more source